ERASCA INC. - COMMON

Erasca Reports First Quarter 2025 Business Updates and Financial Results

13 май 2025 13:05:01 Источник Nasdaq GlobeNewswire

Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

13 май 2025 05:00:00 Источник Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Securities Health Care Conference

07 май 2025 05:00:00 Источник Nasdaq GlobeNewswire

Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting

29 апр 2025 13:05:00 Источник Nasdaq GlobeNewswire

Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting

25 мар 2025 13:31:00 Источник Nasdaq GlobeNewswire

Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results

20 мар 2025 13:01:00 Источник Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

31 янв 2025 05:00:00 Источник Nasdaq GlobeNewswire

Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 янв 2025 05:00:00 Источник Nasdaq GlobeNewswire

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

12 ноя 2024 13:01:00 Источник Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences

05 ноя 2024 05:00:00 Источник Nasdaq GlobeNewswire

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

24 окт 2024 05:00:00 Источник Nasdaq GlobeNewswire

Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium

25 сен 2024 05:00:00 Источник Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences in September

29 авг 2024 05:00:00 Источник Nasdaq GlobeNewswire

Erasca Reports Second Quarter 2024 Business Updates and Financial Results

12 авг 2024 13:01:00 Источник Nasdaq GlobeNewswire

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma

18 июн 2024 05:00:00 Источник Nasdaq GlobeNewswire

Erasca to Present at Upcoming Investor Conferences in June

29 май 2024 05:00:00 Источник Nasdaq GlobeNewswire

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

21 май 2024 13:05:00 Источник Nasdaq GlobeNewswire

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

16 май 2024 17:02:00 Источник Nasdaq GlobeNewswire

Erasca Announces Pricing of Underwritten Offering of Common Stock

16 май 2024 17:00:00 Источник Nasdaq GlobeNewswire

Erasca Reports First Quarter 2024 Business Updates and Financial Results

08 май 2024 13:01:00 Источник Nasdaq GlobeNewswire